# MYQORZO® (aficamten) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aficamten

> The FDA approved MYQORZO® (aficamten), sponsored by CYTOKINETICS INC (CYTK), on December 19, 2025 for to treat symptomatic obstructive hypertrophic cardiomyopathy.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is MYQORZO® (aficamten) FDA approved?

Yes. The FDA approved MYQORZO® (aficamten), sponsored by CYTOKINETICS INC (CYTK), on December 19, 2025 for to treat symptomatic obstructive hypertrophic cardiomyopathy. FDA novel drug approvals: "Myqorzo | aficamten | 12/19/2025 | To treat symptomatic obstructive hypertrophic cardiomyopathyDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/aficamten)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/aficamten#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | MYQORZO® (aficamten) |
| Codes | CK-274 |
| Sponsor | CYTOKINETICS INC (CYTK) https://sec-api.dev/companies/cytk/catalysts |
| Indications | [ohcm](https://sec-api.dev/indications/ohcm), obstructive hcm, symptomatic ohcm, non-obstructive hcm, with obstructive hypertrophic cardiomyopathy, To treat symptomatic obstructive hypertrophic cardiomyopathy, [Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy](https://sec-api.dev/indications/symptomatic-non-obstructive-hypertrophic-cardiomyopathy) |
| Modality |  |
| FDA designations | breakthrough, orphan, priority review |

## Timeline

### Dec 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-02-27, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001193125-26-076495): "In December 2023, we announced positive topline results from SEQUOIA-HCM, the Phase 3 trial for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-267059): "In December 2023, we announced positive topline results from SEQUOIA-HCM, the Phase 3 trial for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105108): "In December 2023, we announced positive topline results from SEQUOIA-HCM, the Phase 3 trial for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000095017025105108/cytk-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-064529): "In December 2023, we announced positive topline results from SEQUOIA-HCM, the Phase 3 trial for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000095017025064529/cytk-20250331.htm
- SEC Form 10-K (accession 0000950170-25-029206): "In December 2023, we announced positive topline results from SEQUOIA-HCM, the Phase 3 trial for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm

### Nov 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-02-27, last confirmed 2026-02-26.
- SEC Form 10-K (accession 0001193125-26-076495): "In November 2024, we announced that FDA accepted our NDA for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-267059): "In November 2024, we announced that FDA has accepted our NDA for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105108): "In November 2024, we announced that FDA has accepted our NDA for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000095017025105108/cytk-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-064529): "In November 2024, we announced that FDA has accepted our NDA for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000095017025064529/cytk-20250331.htm
- SEC Form 10-K (accession 0000950170-25-029206): "In November 2024, we announced that FDA has accepted our NDA for aficamten." https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm

### May 2025: topline data readout

- Status: scheduled. Date confidence: month.
- First seen 2025-01-10, last confirmed 2025-05-06.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-064432): "We expect to share topline results in May 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-029017): "Topline Results from MAPLE-HCM Expected in Q2 2025" https://www.sec.gov/Archives/edgar/data/1061983/000095017025029017/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004097): "These include aficamten for obstructive hypertrophic cardiomyopathy, which has a U.S. Prescription Drug User Fee Act target action date of September 26, 2025, and pelacarsen, which targets elevated Lp(a) in cardiovascular disease and for which topline results are expected in 2025." https://www.sec.gov/Archives/edgar/data/1802768/000119312525004097/d921741dex991.htm

### September 26, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2025-11-05, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001193125-25-267059): "For example, the FDA recently accepted and filed our NDA for aficamten for the treatment of oHCM and assigned the NDA a standard review with a PDUFA target action date of September 26, 2025, which was subsequently extended to December 26, 2025 as a result of FDA considering our submission of a proposed REMS to be a major amendment to the NDA." https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm

### September 26, 2025: PDUFA date

- Status: delayed. Date confidence: exact. Indication: oHCM.
- First seen 2025-01-10, last confirmed 2025-11-05.
- SEC Form 10-K (accession 0000950170-25-029206): "We have submitted an NDA to FDA for aficamten for the treatment of oHCM, which was accepted for filing with a PDUFA target action date of September 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-029017): "The NDA was assigned standard review with a Prescription Drug User Fee Act (PDUFA) target action date of September 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025029017/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-005038): "Aficamten PDUFA date is September 26, 2025." https://www.sec.gov/Archives/edgar/data/1802768/000119312525005038/d919433dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004097): "These include aficamten for obstructive hypertrophic cardiomyopathy, which has a U.S. Prescription Drug User Fee Act target action date of September 26, 2025, and pelacarsen, which targets elevated Lp(a) in cardiovascular disease and for which topline results are expected in 2025." https://www.sec.gov/Archives/edgar/data/1802768/000119312525004097/d921741dex991.htm
- SEC Form 10-K (accession 0001802768-25-000010): "The FDA has assigned the NDA a PDUFA date of September 26, 2025." https://www.sec.gov/Archives/edgar/data/1802768/000180276825000010/rprx-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-023988): "The FDA has assigned the NDA a Prescription Drug User Fee Act date of September 26, 2025." https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/d929959dex991.htm
- SEC Form 10-Q (accession 0001558370-25-006857): "In December 2024, the FDA accepted the aficamten New Drug Application (NDA) with a Prescription Drug User Fee Act (PDUFA) target action date set for September 26, 2025." https://www.sec.gov/Archives/edgar/data/1710072/000155837025006857/ewtx-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-002006): "In December 2024, the FDA accepted the aficamten New Drug Application (NDA) with a Prescription Drug Free User Act (PDUFA) target action date set for September 26, 2025." https://www.sec.gov/Archives/edgar/data/1710072/000155837025002006/ewtx-20241231x10k.htm
- SEC Form 10-Q (accession 0001193125-25-267059): "The FDA accepted and filed the NDA and assigned the NDA a standard review with a PDUFA target action date of September 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-105108): "The FDA accepted and filed the NDA and assigned the NDA a standard review with a PDUFA target action date of September 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025105108/cytk-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-064529): "The FDA accepted and filed the NDA and assigned the NDA a standard review with a PDUFA target action date of September 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025064529/cytk-20250331.htm
- SEC Form 10-K (accession 0000950170-25-029206): "The FDA accepted and filed the NDA and assigned the NDA a standard review with a PDUFA target action date of September 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm

### December 19, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat symptomatic obstructive hypertrophic cardiomyopathy.
- First seen 2025-12-19, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Myqorzo | aficamten | 12/19/2025 | To treat symptomatic obstructive hypertrophic cardiomyopathyDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
- openFDA Drugs@FDA: "NDA219083 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20251219, review_priority STANDARD; sponsor_name CYTOKINETICS; product MYQORZO (AFICAMTEN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219083%22
- SEC Form 8-K (accession 0001193125-25-326778): "On December 19, 2025, Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration ("FDA") has approved MYQORZO (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy ("oHCM") to improve functional capacity and symptoms." https://www.sec.gov/Archives/edgar/data/1061983/000119312525326778/cytk-20251219.htm
- SEC Form 10-Q (accession 0001193125-26-447408): "MYQORZO for adults with symptomatic oHCM was approved by the FDA in December 2025 and our first commercial sale of MYQORZO occurred in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/cytk-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-447408): "In December 2025, MYQORZO was approved by the FDA, and accordingly, our sales and marketing expenses will increase significantly as we engage in commercialization activities in the United States." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/cytk-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-447408): "With the recent FDA approval of MYQORZO in December 2025, we have only recently started generating revenues from the commercial sale of our drugs." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/cytk-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-338217): "MYQORZO for adults with symptomatic oHCM was approved by the FDA in December 2025 and our first commercial sale of MYQORZO occurred in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-338217): "In December 2025, MYQORZO was approved by the FDA, and accordingly, our sales and marketing expenses will increase significantly as we engage in commercialization activities in the United States." https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-338217): "With the recent FDA approval of MYQORZO in December 2025, we have only recently started generating revenues from the commercial sale of our drugs." https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-206364): "In December 2025, MYQORZO was approved by the FDA, and accordingly, our sales and marketing expenses will increase significantly as we engage in commercialization activities in the United States." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-206364): "With the recent FDA approval of MYQORZO in December 2025, we have only recently started generating revenues from the commercial sale of our drugs." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-206364): "MYQORZO for adults with symptomatic oHCM was approved by the FDA in December 2025 and our first commercial sale of MYQORZO occurred in the first quarter of 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm

### December 26, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact. Indication: with obstructive hypertrophic cardiomyopathy.
- First seen 2025-05-01, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-266842): "Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track" https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-266842): "Continued to support the review of the New Drug Application (NDA) for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM) by the U.S. Food and Drug Administration (FDA) ahead of the Prescription Drug User Fee Act (PDUFA) action date of December 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm
- SEC Form 8-K (accession 0001193125-25-204991): "The Prescription Drug User Fee Act ("PDUFA") target action date for the NDA for aficamten remains December 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000119312525204991/d66361d8k.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-112570): "Aficamten is an investigational drug candidate currently under regulatory review in the U.S; the Food and Drug Administration (FDA) is reviewing a New Drug Application (NDA) for aficamten with a Prescription Drug User Fee Act (PDUFA) target action date of December 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025112570/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-112570): "Aficamten is currently under regulatory review in the U.S, where the FDA is reviewing a New Drug Application (NDA) for aficamten with a Prescription Drug User Fee Act (PDUFA) target action date of December 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025112570/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-112564): "Aficamten is an investigational drug candidate currently under regulatory review in the U.S; the Food and Drug Administration (FDA) is reviewing a New Drug Application (NDA) for aficamten with a Prescription Drug User Fee Act (PDUFA) target action date of December 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025112564/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-112564): "Aficamten is currently under regulatory review in the U.S, where the FDA is reviewing a New Drug Application (NDA) for aficamten with a Prescription Drug User Fee Act (PDUFA) target action date of December 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025112564/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-064432): "PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025" https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-064432): "The U.S. Food & Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) target action date for the New Drug Application (NDA) for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM) to December 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm
- SEC Form 8-K (accession 0000950170-25-061847): "Cytokinetics, Incorporated ("Cytokinetics") today announced that the U.S. Food and Drug Administration ("FDA") has extended the Prescription Drug User Fee Act ("PDUFA") action date for the New Drug Application ("NDA") for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy ("oHCM") to December 26, 2025." https://www.sec.gov/Archives/edgar/data/1061983/000095017025061847/cytk-20250429.htm
- SEC Form 10-Q (accession 0001193125-25-267059): "The earliest we might reasonably expect to commence commercial sales and record revenues is following the PDUFA target action date of December 26, 2025 for the NDA for aficamten in oHCM." https://www.sec.gov/Archives/edgar/data/1061983/000119312525267059/cytk-20250930.htm
- FDA novel drug approvals: "Myqorzo | aficamten | 12/19/2025 | To treat symptomatic obstructive hypertrophic cardiomyopathyDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025

### Jan 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Stage: 3. Indication: obstructive HCM.
- First seen 2026-05-05, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001193125-26-447408): "Finally, in January 2026 we submitted, and the FDA subsequently accepted for filing, a supplemental NDA for MYQORZO to the FDA requesting to include the results of MAPLE-HCM, a Phase 3 randomized, double blind, active-comparator clinical trial of aficamten as monotherapy compared to metoprolol as a monotherapy in patients with obstructive HCM, in the label." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/cytk-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-338217): "Finally, in January 2026 we submitted, and the FDA subsequently accepted for filing, a supplemental NDA for MYQORZO to the FDA requesting to include the results of MAPLE-HCM, a Phase 3 randomized, double blind, active-comparator clinical trial of aficamten as monotherapy compared to metoprolol as a monotherapy in patients with obstructive HCM, in the label." https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-206364): "Finally, in January 2026 we submitted, and the FDA subsequently accepted for filing, a supplemental NDA for MYQORZO to the FDA requesting to include the results of MAPLE-HCM, a Phase 3 randomized, double blind, active-comparator clinical trial of aficamten as monotherapy compared to metoprolol as a monotherapy in patients with obstructive HCM, in the label." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm

### May 5, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-05-06, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-206360): ""In addition, today we shared positive topline results from ACACIA-HCM in non-obstructive HCM showing that aficamten improved both symptoms and maximal exercise performance, a milestone achievement that opens the aperture for aficamten to potentially address the entire spectrum of HCM." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-206364): "On May 5, 2026, we announced positive topline results from ACACIA-HCM." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-206364): "On May 5, 2026, we announced positive topline results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic nHCM." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-266842): "We expect to share topline results of the primary cohort (excluding Japan) in Q2 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312525266842/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-104962): "We expect to share topline results of the primary cohort (excluding Japan) in 1H 2026." https://www.sec.gov/Archives/edgar/data/1061983/000095017025104962/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-064432): "We expect to share topline results in 1H 2026." https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-064432): "Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026" https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm

### August 31, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06081894 (A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-31 (ACTUAL); Lead Sponsor Cytokinetics." https://clinicaltrials.gov/study/NCT06081894

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06081894 (A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-31 (ACTUAL); Lead Sponsor Cytokinetics." https://clinicaltrials.gov/study/NCT06081894

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: non-obstructive HCM.
- First seen 2026-08-06, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-447198): "Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-447198): "Examples of such statements include, but are not limited to, statements, express or implied, relating to our plans to submit a Supplemental NDA for aficamten in non-obstructive HCM in the fourth quarter of 2026 and a Type II Variation in the European Union in early 2027, and the timing and outcome of any related regulatory review" https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-372456): "Based on the positive results from ACACIA-HCM, Cytokinetics plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for aficamten for the treatment of adult patients with symptomatic nHCM in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-372456): "Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338021): "Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338021): "our plans to submit a Supplemental NDA for aficamten in non-obstructive HCM in the fourth quarter of 2026, and the timing and outcome of any related regulatory review" https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-447408): "Based on these results, we plan to submit a supplemental NDA to the FDA for aficamten for the treatment of adult patients with symptomatic nHCM in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/cytk-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-447408): "Based on the positive results from ACACIA-HCM, we plan to submit a supplemental NDA to the FDA for aficamten for the treatment of adult patients with symptomatic nHCM in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/cytk-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-447198): "We expect to file a Supplemental New Drug Application (NDA) for nHCM in Q4 2026 and a Type II Variation in the European Union in early 2027." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-338021): "We expect to file a Supplemental NDA for nHCM in Q4 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-ex99_1.htm

### November 14, 2026: PDUFA date

- Status: scheduled. Date confidence: exact. Indication: Symptomatic Obstructive HCM.
- First seen 2026-05-05, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-206360): "MYQORZO Approved by the European Commission for Adults with Symptomatic Obstructive HCM; Supplemental NDA for MAPLE-HCM Accepted for Filing by FDA with PDUFA Date of November 14, 2026" https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-206420): "PDUFA November 14, 2026* Access to further capital:" https://www.sec.gov/Archives/edgar/data/1061983/000119312526206420/d124879dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-206360): "The Supplemental New Drug Application for MAPLE-HCM was accepted for filing by the U.S. Food and Drug Administration (FDA) with a PDUFA date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-447408): "The FDA assigned a standard review classification to the sNDA with a PDUFA date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/cytk-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-338217): "The FDA assigned a standard review classification to the sNDA with a PDUFA date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-206364): "The FDA assigned a standard review classification to the sNDA with a PDUFA date of November 14, 2026." https://www.sec.gov/Archives/edgar/data/1061983/000119312526206364/cytk-20260331.htm

### early 2027: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-11-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-447198): "We expect to present topline data in early 2027." https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm

### January 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Pediatric; Symptomatic Obstructive Hypertrophic Cardiomyopathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06412666 (A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Cytokinetics." https://clinicaltrials.gov/study/NCT06412666

### Jan to Apr 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Pediatric; Symptomatic Obstructive Hypertrophic Cardiomyopathy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06412666 (A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01 (ESTIMATED); Lead Sponsor Cytokinetics." https://clinicaltrials.gov/study/NCT06412666

## Same indication

- [EDG-7500](https://sec-api.dev/pdufa/edg-7500) (EWTX)

Calendar months: [September 2025](https://sec-api.dev/fda-calendar/2025-09), [November 2026](https://sec-api.dev/fda-calendar/2026-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aficamten.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MYQORZO® (aficamten) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aficamten

```bibtex
@misc{secapidev_pdufa_aficamten_20261116,
  title        = {MYQORZO® (aficamten) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aficamten}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aficamten_20261116","title":"MYQORZO® (aficamten) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aficamten","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
